COMPANY PRODUCT TYPE THERAPEUTIC AREA INDICATION PHASE PRODUCT
AbbVie ABBV-400 Biodrugs/ Drugs Cancer Solid Tumours 1PhI ABBV-400
Therapeutic area: Cancer
AbbVie ABBV-916 Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII ABBV-916
Therapeutic area: Central Nervous System
AbbVie ABBV-647 Biodrugs/ Drugs Cancer Solid Tumours 1PhI ABBV-647
Therapeutic area: Cancer
AbbVie ABBV-181 Biodrugs/ Drugs Cancer Solid Tumours 1PhI ABBV-181
Therapeutic area: Cancer
AbbVie ABBV-927 Biodrugs/ Drugs Cancer Solid Tumours 2PhII ABBV-927
Therapeutic area: Cancer
AbbVie Lutikizumab Biodrugs/ Drugs Autoimmune & Inflammation Hidradenitis Suppurativa 2PhII Lutikizumab
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-637 Biodrugs/ Drugs Cancer Solid Tumours 1PhI ABBV-637
Therapeutic area: Cancer
AbbVie ABBV-368 Biodrugs/ Drugs Cancer Solid Tumours 1PhI ABBV-368
Therapeutic area: Cancer
AbbVie ALPN-101 Biodrugs/ Drugs Autoimmune & Inflammation Systemic lupus erythematosus 2PhII ALPN-101
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-383 Biodrugs/ Drugs Cancer Multiple Myeloma 1PhI ABBV-383
Therapeutic area: Cancer
AbbVie Skyrizi Biodrugs/ Drugs Autoimmune & Inflammation Ulcerative colitis 3PhIII Skyrizi
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-154 Biodrugs/ Drugs Autoimmune & Inflammation Polimialgia reumática y Enfermedad de Crohn 2PhII ABBV-154
Therapeutic area: Autoimmune & Inflammation
AbbVie ABBV-155 Biodrugs/ Drugs Cancer Solid and Hematologic Tumors 1PhI ABBV-155
Therapeutic area: Cancer
AbbVie AGN-151607 Biodrugs/ Drugs Others Post-Operative Atrial Fibrillation 2PhII AGN-151607
Therapeutic area: Others
AbbVie AL002 Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII AL002
Therapeutic area: Central Nervous System
AbbVie Telisotuzumab vedotin (ABBV-399) Biodrugs/ Drugs Cancer Non-Small Cell Lung Cancer 3PhIII Telisotuzumab vedotin (ABBV-399)
Therapeutic area: Cancer
AbbVie Elezanumab (ABT-555) Biodrugs/ Drugs Central Nervous System "Spinal Cord Injury N ∕ A Acute Ischemic Stroke" 2PhII Elezanumab (ABT-555)
Therapeutic area: Central Nervous System
AbbVie Epcoritamab Biodrugs/ Drugs Cancer "First-line Large B-cell Lymphoma US , EU Relapsed ∕ Refractory Follicular Lymphoma N ∕ A B-cell Non-Hodgkin lymphoma N ∕ A Relapsed ∕ Refractory Chronic Lymphocytic Leukemia N ∕ A Richter's Syndrome" 3PhIII Epcoritamab
Therapeutic area: Cancer
AbbVie ABBV-151 Biodrugs/ Drugs Cancer Solid Tumours 2PhII ABBV-151
Therapeutic area: Cancer
AbbVie ABBV-CX-2029 Biodrugs/ Drugs Cancer Solid and Hematologic Tumors 2PhII ABBV-CX-2029
Therapeutic area: Cancer
AbbVie Eftoza Biodrugs/ Drugs Cancer Solid and Hematologic Tumors 1PhI Eftoza
Therapeutic area: Cancer
Amgen talimogene laherparepec Biodrugs/ Drugs Cancer
Digestive System
Hepatocellular carcinoma (HCC) and metastatic liver tumors (non-HCC) 1PhI talimogene laherparepec
Therapeutic area: Cancer / Digestive System
Amgen efavaleucina alfa Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Ulcerative colitis 2PhII efavaleucina alfa
Therapeutic area: Autoimmune & Inflammation / Digestive System
Amgen AMG 256 Biodrugs/ Drugs Cancer Advanced solid tumors 1PhI AMG 256
Therapeutic area: Cancer
Amgen tarlatamab Biodrugs/ Drugs Cancer
Respiratory and Pulmonary system
Small cell lung cancer 1PhI tarlatamab
Therapeutic area: Cancer / Respiratory and Pulmonary system
Amgen sotorasib Biodrugs/ Drugs Cancer
Respiratory and Pulmonary system
Previously treated, locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with the p.G12C mutation in KRAS 3PhIII sotorasib
Therapeutic area: Cancer / Respiratory and Pulmonary system
Amgen carfilzomib Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Multiple myeloma in relapse 2PhII carfilzomib
Therapeutic area: Blood and Lymphatic systems / Cancer
Amgen AMG 404 Biodrugs/ Drugs Cancer Advanced solid tumors 1PhI AMG 404
Therapeutic area: Cancer
Amgen sotorasib Biodrugs/ Drugs Cancer
Digestive System
Subjects with previously treated metastatic colorectal cancer with KRAS G12C mutation 3PhIII sotorasib
Therapeutic area: Cancer / Digestive System
Amgen sotorasib Biodrugs/ Drugs Cancer
Digestive System
Respiratory and Pulmonary system
Non-small cell lung cancer, colorectal cancer, and other solid tumors 1PhI sotorasib
Therapeutic area: Cancer / Digestive System / Respiratory and Pulmonary system
Amgen carfilzomib Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Relapsed or refractory multiple myeloma 3PhIII carfilzomib
Therapeutic area: Blood and Lymphatic systems / Cancer
Amgen Rocatinlimab Biodrugs/ Drugs Dermatology Atopic Dermatitis 3PhIII Rocatinlimab
Therapeutic area: Dermatology
Amgen sotorasib Biodrugs/ Drugs Cancer
Respiratory and Pulmonary system
Advanced solid tumors with the KRAS G12C mutation 1PhI sotorasib
Therapeutic area: Cancer / Respiratory and Pulmonary system
Amgen sotorasib Biodrugs/ Drugs Cancer
Respiratory and Pulmonary system
Untreated stage IV non-small cell lung cancer (NSCLC) with p.G12C mutation in KRAS 2PhII sotorasib
Therapeutic area: Cancer / Respiratory and Pulmonary system
Amgen blinatumomab Biodrugs/ Drugs Blood and Lymphatic systems Newly diagnosed Philadelphia Chromosome (Ph) Negative B-Precursor Acute Lymphoblastic Leukemia (ALL) 3PhIII blinatumomab
Therapeutic area: Blood and Lymphatic systems
Amgen Olpasiran Biodrugs/ Drugs Cardiovascular and circulatory systems Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD) and elevated lipoprotein 3PhIII Olpasiran
Therapeutic area: Cardiovascular and circulatory systems
Amgen sotorasib Biodrugs/ Drugs Cancer
Respiratory and Pulmonary system
Previously treated locally advanced unresectable or metastatic non-small cell lung cancer with the KRAS p.G12C mutation 3PhIII sotorasib
Therapeutic area: Cancer / Respiratory and Pulmonary system
Amgen romiplostim Biodrugs/ Drugs Blood and Lymphatic systems Chemotherapy-induced thrombocytopenia (CIT) 3PhIII romiplostim
Therapeutic area: Blood and Lymphatic systems
Amgen blinatumomab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Refractory/Relapsed Precursor B-Acute Lymphoblastic Leukemia (B-ALL R/R) 1PhI blinatumomab
Therapeutic area: Blood and Lymphatic systems / Cancer
Amgen bemarituzumab Biodrugs/ Drugs Cancer
Digestive System
overexpression of FGFR2b (FORTITUDE-301) 1PhI bemarituzumab
Therapeutic area: Cancer / Digestive System
Amgen etelcalcetida Biodrugs/ Drugs Blood and Lymphatic systems Secondary hyperparathyroidism undergoing hemodialysis 3PhIII etelcalcetida
Therapeutic area: Blood and Lymphatic systems
Amgen Repatha Biodrugs/ Drugs Cardiovascular and circulatory systems A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke 3PhIII Repatha
Therapeutic area: Cardiovascular and circulatory systems
Amgen blinatumomab Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Adults with Refractory/Relapsed B-Precursor ALL (B-ALL R/R) 1PhI blinatumomab
Therapeutic area: Blood and Lymphatic systems / Cancer
Amgen AMG 199 Biodrugs/ Drugs Cancer
Digestive System
Gastric and gastroesophageal junction cancer 1PhI AMG 199
Therapeutic area: Cancer / Digestive System
Amgen erenumab Biodrugs/ Drugs Analgesia & Pain
Central Nervous System
Migraine 4Reg. erenumab
Therapeutic area: Analgesia & Pain / Central Nervous System
Amgen erenumab Biodrugs/ Drugs Analgesia & Pain
Central Nervous System
Episodic migraine (high frequency) 4Reg. erenumab
Therapeutic area: Analgesia & Pain / Central Nervous System
Amgen bemarituzumab Biodrugs/ Drugs Cancer
Digestive System
Advanced and untreated gastric and gastroesophageal junction cancer with overexpression of FGFR2b 1PhI bemarituzumab
Therapeutic area: Cancer / Digestive System
Amgen Evenity Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes A Randomized, Double blind, Placebo controlled, Ascending Multiple dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Romosozumab in Children and Adolescents with Osteogenesis Imperfecta 1PhI Evenity
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Amgen tarlatamab Biodrugs/ Drugs Cancer Neuroendocrine Prostate Cancer (PNES) 1PhI tarlatamab
Therapeutic area: Cancer
Amgen carfilzomib Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Recurrent or refractory acute lymphoblastic leukemia 1PhI carfilzomib
Therapeutic area: Blood and Lymphatic systems / Cancer
Amgen bemarituzumab Biodrugs/ Drugs Cancer
Digestive System
Previously untreated advanced gastric or gastroesophageal junction cancer with overexpression of FGFR2b 3PhIII bemarituzumab
Therapeutic area: Cancer / Digestive System
Amgen tarlatamab Biodrugs/ Drugs Cancer
Respiratory and Pulmonary system
Small cell lung cancer 1PhI tarlatamab
Therapeutic area: Cancer / Respiratory and Pulmonary system
Amgen apremilast Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
" EB:inflamación en los vasos sanguineos, se manifiestan ulceras bucales/genitales y lesiones en los ojos/piel AIJ:inflamación de las articulaciones con desorden psoriasico que afecta a pts pediatricos " 3PhIII apremilast
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Amgen bemarituzumab Biodrugs/ Drugs Cancer Squamous non-small cell lung cancer 1PhI bemarituzumab
Therapeutic area: Cancer
Amgen tarlatamab Biodrugs/ Drugs Cancer
Respiratory and Pulmonary system
Relapsed/refractory small cell lung cancer 3PhIII tarlatamab
Therapeutic area: Cancer / Respiratory and Pulmonary system
Amgen apremilast Biodrugs/ Drugs Autoimmune & Inflammation Subjects with active Behçet's disease 3PhIII apremilast
Therapeutic area: Autoimmune & Inflammation
Amgen apremilast Biodrugs/ Drugs Autoimmune & Inflammation Juvenile psoriatic arthritis 3PhIII apremilast
Therapeutic area: Autoimmune & Inflammation
Amgen AMG 305 Biodrugs/ Drugs Cancer Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors 1PhI AMG 305
Therapeutic area: Cancer
Amgen talimogén laherparepvec Biodrugs/ Drugs Cancer
Dermatology
Melanoma stage IIIB to IVM1d unresectable/metastatic 2PhII talimogén laherparepvec
Therapeutic area: Cancer / Dermatology
Amgen acapatamab Biodrugs/ Drugs Cancer Metastatic castration-resistant prostate cancer (mCRPC) 2PhII acapatamab
Therapeutic area: Cancer
Amgen AMG 133 Biodrugs/ Drugs Metabolic / Endocrinology Obesity 2PhII AMG 133
Therapeutic area: Metabolic / Endocrinology
Amgen Xaluritamig Biodrugs/ Drugs Cancer A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer 1PhI Xaluritamig
Therapeutic area: Cancer
Celavista Mito-Biogénesis Retriacyl Biodrugs/ Drugs Ophthalmology and optometry Retinitis Pigmentosa 3PhIII Retriacyl
Therapeutic area: Ophthalmology and optometry
Gilead Sciences Vesatolimod Biodrugs/ Drugs Autoimmune & Inflammation HIV cure 2PhII Vesatolimod
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences Sacituzumab govitecan-hziy Biodrugs/ Drugs Cancer 2-3L non-small cell lung cancer 3PhIII Sacituzumab govitecan-hziy
Therapeutic area: Cancer
Gilead Sciences Magrolimab + azacitidine Biodrugs/ Drugs Cancer 1L TP53m acute myeloid leukemia 3PhIII Magrolimab + azacitidine
Therapeutic area: Cancer
Gilead Sciences Lenacapavir Biodrugs/ Drugs Autoimmune & Inflammation Long-acting HIV treatment for virologically suppressed people living with HIV 2PhII Lenacapavir
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences Domvanalimab + zimberelimab + chemotherapy Biodrugs/ Drugs Cancer 1L non-small cell lung cancer 3PhIII Domvanalimab + zimberelimab + chemotherapy
Therapeutic area: Cancer
Gilead Sciences AB308 + zimberelimab Biodrugs/ Drugs Cancer Advanced cancers 1PhI AB308 + zimberelimab
Therapeutic area: Cancer
Gilead Sciences Obeldesivir Biodrugs/ Drugs Others COVID-19 3PhIII Obeldesivir
Therapeutic area: Others
Gilead Sciences Sacituzumab govitecan-hziy + pembrolizumab Biodrugs/ Drugs Cancer 1L non-small cell lung cancer 2PhII Sacituzumab govitecan-hziy + pembrolizumab
Therapeutic area: Cancer
Gilead Sciences CCR8 (GS-1811) Biodrugs/ Drugs Cancer Advanced Cancers 1PhI CCR8 (GS-1811)
Therapeutic area: Cancer
Gilead Sciences Lenacapavir / bictegravir  Biodrugs/ Drugs Autoimmune & Inflammation HIV treatment for virologically suppressed treatment-experienced people living with HIV 3PhIII Lenacapavir / bictegravir 
Therapeutic area: Autoimmune & Inflammation
Gilead Sciences Magrolimab + chemotherapy/IO combinations Biodrugs/ Drugs Cancer Head and neck squamous cell carcinoma 2PhII Magrolimab + chemotherapy/IO combinations
Therapeutic area: Cancer
Gilead Sciences MCL1 inhibitor (GS-9716) Biodrugs/ Drugs Cancer Advanced cancers 1PhI MCL1 inhibitor (GS-9716)
Therapeutic area: Cancer
Gilead Sciences Trodelvy Biodrugs/ Drugs Cancer 2L metastatic urothelial carcinoma 3PhIII Trodelvy
Therapeutic area: Cancer
Gilead Sciences Axicabtagene ciloleucel Biodrugs/ Drugs Cancer 2L+ high-risk follicular lymphoma 3PhIII Axicabtagene ciloleucel
Therapeutic area: Cancer
Gilead Sciences Sacituzumab govitecan-hziy + pembrolizumab Biodrugs/ Drugs Cancer Adjuvant triple-negative breast cancer 3PhIII Sacituzumab govitecan-hziy + pembrolizumab
Therapeutic area: Cancer
Gilead Sciences Sacituzumab govitecan-hziy + combinations  Biodrugs/ Drugs Cancer 1L metastatic urothelial carcinoma 2PhII Sacituzumab govitecan-hziy + combinations 
Therapeutic area: Cancer
Gilead Sciences Axicabtagene ciloleucel  Biodrugs/ Drugs Cancer 1L high-risk large B-cell lymphoma 3PhIII Axicabtagene ciloleucel 
Therapeutic area: Cancer
Gilead Sciences Sacituzumab govitecan-hziy + pembrolizumab Biodrugs/ Drugs Cancer 1L metastatic triple-negative breast cancer (PD-L1+) 3PhIII Sacituzumab govitecan-hziy + pembrolizumab
Therapeutic area: Cancer
Gilead Sciences Magrolimab + chemotherapy/SG combinations Biodrugs/ Drugs Cancer Metastatic triple-negative breast cancer 2PhII Magrolimab + chemotherapy/SG combinations
Therapeutic area: Cancer
Gilead Sciences Etrumadenant + zimberelimab combinations Biodrugs/ Drugs Cancer Metastatic colorectal cancer 2PhII Etrumadenant + zimberelimab combinations
Therapeutic area: Cancer
Gilead Sciences Brexucabtagene autoleucel Biodrugs/ Drugs Cancer Pediatric acute lymphocytic leukemia 2PhII Brexucabtagene autoleucel
Therapeutic area: Cancer
Gilead Sciences Sacituzumab govitecan-hziy Biodrugs/ Drugs Cancer 1L metastatic triple-negative breast cancer (PD-L1-) 3PhIII Sacituzumab govitecan-hziy
Therapeutic area: Cancer
Gilead Sciences Sacituzumab govitecan-hziy Biodrugs/ Drugs Cancer Basket (Solid tumors) 2PhII Sacituzumab govitecan-hziy
Therapeutic area: Cancer
Gilead Sciences Brexucabtagene autoleucel  Biodrugs/ Drugs Cancer Basket (rare B-cell malignancies) 2PhII Brexucabtagene autoleucel 
Therapeutic area: Cancer
Gilead Sciences Magrolimab + chemotherapy Biodrugs/ Drugs Cancer Solid tumors 2PhII Magrolimab + chemotherapy
Therapeutic area: Cancer
Gilead Sciences Selgantolimod Biodrugs/ Drugs Others HBV cure 2PhII Selgantolimod
Therapeutic area: Others
Gilead Sciences Magrolimab + chemotherapy Biodrugs/ Drugs Cancer Solid tumors 2PhII Magrolimab + chemotherapy
Therapeutic area: Cancer
Gilead Sciences Cilofexor / firsocostat / semaglutide combination Biodrugs/ Drugs Others Nonalcoholic steatohepatitis 2PhII Cilofexor / firsocostat / semaglutide combination
Therapeutic area: Others
Gilead Sciences Magrolimab + azacitidine Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes 1L higher risk myelodysplastic syndrome 3PhIII Magrolimab + azacitidine
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Incyte Biosciences Iberia INCMGA0012 Biodrugs/ Drugs Cancer MSI-H endometrial cancer (In collaboration with MacroGenics) 1PhI INCMGA0012
Therapeutic area: Cancer
Incyte Biosciences Iberia INCMGA0012 Biodrugs/ Drugs Cancer Merkel cell carcinoma (In collaboration with MacroGenics) 2PhII INCMGA0012
Therapeutic area: Cancer
Incyte Biosciences Iberia INCMGA0012 Biodrugs/ Drugs Cancer Anal cancer (In collaboration with MacroGenics) 2PhII INCMGA0012
Therapeutic area: Cancer
Incyte Biosciences Iberia Itacitinib Biodrugs/ Drugs Cancer Chronic graft-versus-host disease 3PhIII Itacitinib
Therapeutic area: Cancer
Incyte Biosciences Iberia INCB01158 Biodrugs/ Drugs Cancer Solid tumors (Co-development with Calithera) 2PhII INCB01158
Therapeutic area: Cancer
Incyte Biosciences Iberia Itacitinib Biodrugs/ Drugs Cancer Non-small cell lung cancer (with osimertinib) (In collaboration with AstraZeneca) 2PhII Itacitinib
Therapeutic area: Cancer
Incyte Biosciences Iberia INCAGN1876 Biodrugs/ Drugs Cancer Solid tumors (Discovery alliance with Agenus) 2PhII INCAGN1876
Therapeutic area: Cancer
Incyte Biosciences Iberia Pemigatinib Biodrugs/ Drugs Cancer Bladder cancer 2PhII Pemigatinib
Therapeutic area: Cancer
Incyte Biosciences Iberia Pemigatinib Biodrugs/ Drugs Cancer Cholangiocarcinoma 2PhII Pemigatinib
Therapeutic area: Cancer
Incyte Biosciences Iberia Pemigatinib Biodrugs/ Drugs Cancer 8p11 MPN 2PhII Pemigatinib
Therapeutic area: Cancer
Incyte Biosciences Iberia Parsaclisib Biodrugs/ Drugs Cancer Follicular lymphoma 2PhII Parsaclisib
Therapeutic area: Cancer
Incyte Biosciences Iberia Parsaclisib Biodrugs/ Drugs Cancer Marginal zone lymphoma 2PhII Parsaclisib
Therapeutic area: Cancer
Incyte Biosciences Iberia Parsaclisib Biodrugs/ Drugs Cancer Mantle cell lymphoma 2PhII Parsaclisib
Therapeutic area: Cancer
Merck KGaA Tepotinib (MET kinase inhibitor) Biodrugs/ Drugs Cancer Non-small cell lung cancer, EGFR mutant, MET amplified 2PhII Tepotinib (MET kinase inhibitor)
Therapeutic area: Cancer
Merck KGaA M9140 (anti-CEACAM5 Ab drug conjugate) Biodrugs/ Drugs Cancer Solid tumors 1PhI M9140 (anti-CEACAM5 Ab drug conjugate)
Therapeutic area: Cancer
Merck KGaA Xevinapant (IAP inhibitor) Biodrugs/ Drugs Cancer Resected, cisplatin-ineligible locally advanced SCCHN 3PhIII Xevinapant (IAP inhibitor)
Therapeutic area: Cancer
Merck KGaA Evobrutinib  (BTK inhibitor) Biodrugs/ Drugs Central Nervous System Relapsing multiple sclerosis 3PhIII Evobrutinib  (BTK inhibitor)
Therapeutic area: Central Nervous System
Merck KGaA Xevinapant (IAP inhibitor) Biodrugs/ Drugs Cancer Unresected, cisplatin-eligible locally advanced squamous cell carcinoma of the head and neck (SCCHN) 3PhIII Xevinapant (IAP inhibitor)
Therapeutic area: Cancer
Merck KGaA Avelumab (anti-PD-L1 inhibitor) Biodrugs/ Drugs Cancer Javelin clinical program - avelumab in: solid tumors, renal cell carcinoma, urothelial carcinoma, merkel cell carcinoma, gastric, Head & Neck, lung, ovarian, gastroesophagic junction) 4Reg. Avelumab (anti-PD-L1 inhibitor)
Therapeutic area: Cancer
Merck KGaA Enpatoran (TLR7/8 antagonist) Biodrugs/ Drugs Others Systemic lupus erythematosus 2PhII Enpatoran (TLR7/8 antagonist)
Therapeutic area: Others
Merck KGaA M1774 (ATR inhibitor) Biodrugs/ Drugs Cancer DDRiver Solid Tumors 320. ATR inhibitor in combination with Dna Damage Response Inhibitors or Immune Checkpoint Inhibitors 1PhI M1774 (ATR inhibitor)
Therapeutic area: Cancer
Merck KGaA M1774 (ATR inhibitor) Biodrugs/ Drugs Cancer DDRiver Solid Tumors 301. ATR inhibitor monotherapy and in combination with niraparib 1PhI M1774 (ATR inhibitor)
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Recurrent or Progressive Metastatic Bladder Cancer. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Trastuzumab + Chemotherapy with or without Pembrolizumab as First-line Treatment in Participants With HER2 Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Advanced Solid Tumors Analyzed for Predictive Biomarkers 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib in combination with Pembrolizumab in Participants with Metastatic Colorectal Cancer who have received and progressed on or after or became intolerant to prior treatment 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Vaxelis Vaccines Infections Vaccination against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b (Paediatric population) 3PhIII Vaxelis
Therapeutic area: Infections
MSD Islatravir Biodrugs/ Drugs Infections HIV Infection 3PhIII Islatravir
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Chemo +/- Pembrolizumab as Perioperative Therapy for Resectable Stage IIB or IIIA Non-small Cell Lung Cancer. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/MK-7684 Biodrugs/ Drugs Cancer Basket study of MK-7684A, a Co formation of Vibostolimab (MK-7684) with Pembrolizumab (MK-3475), with or without other anticancer therapies in participants with selected solid tumors 2PhII Pembrolizumab/MK-7684
Therapeutic area: Cancer
MSD Anacetrapib Biodrugs/ Drugs Metabolic / Endocrinology Coronary Heart Disease (CHD) or CHD Risk- Equivalent Disease 3PhIII Anacetrapib
Therapeutic area: Metabolic / Endocrinology
MSD MK-5890/Pembrolizumab Biodrugs/ Drugs Cancer Selected Advanced Solid Tumors 1PhI MK-5890/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First Line Progression 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab with or without Chemotherapy as First-line Treatment in Participants With HER2 negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced HCC 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumanb/Enfortumab Biodrugs/ Drugs Cancer Perioperative EV + Pembrolizumab vs Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer 3PhIII Pembrolizumanb/Enfortumab
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Pembro plus Olaparib Vs Abiraterone Acetate or Enzalutamide in participants w/metastatic castration-resistant prostate cancer who are unselected for homologous recomb repair defects & have failed prior treatm. w/one next-generation hormonal agent and chem 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Favezelimab/Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects with Advanced Solid Tumor 1PhI Favezelimab/Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Subjects with histologically confirmed diagnosis of melanoma with unresectable or metastatic melanoma. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembroluzimab given concomitantly with chemoradiation in subjects with locally advanced head and neck squamous cell carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Peri-operative Pembrolizumab + Neoadjuvant Chemotherapy vs. Placebo + Neoadjuvant Chemotherapy for Cis-Eligible Muscle Invasive Bladder Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab plus Chemotherapy for the Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD ZERBAXA Biodrugs/ Drugs Infections Pediatric participants with nosocomial pneumonia (HABP/VABP) 1PhI ZERBAXA
Therapeutic area: Infections
MSD Inactivated VZV Vaccine Vaccines Blood and Lymphatic systems Adult Patients with Solid Tumor or Hematologic Malignancy 3PhIII Inactivated VZV Vaccine
Therapeutic area: Blood and Lymphatic systems
MSD Pembrolizumab Biodrugs/ Drugs Cancer Chemotherapy with or without Pembrolizumab in TKI-resistant EGFR-mutated Tumors in Metastatic Non-Squamous Non-small Cell Lung Cancer. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab administrated with Platinum doublet chemotherapy in Metastasic Squamous or Nonsquamous non small cell lung cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/MK-7684 or MK-4830 or MK-5890 or MK-0482 Biodrugs/ Drugs Cancer KEYMAKER-U01 Master study: A phase 2, Umbrella study with Rolling Arms of Investigational Agents with either Pembrolizumab in combination with Chemotherapy or with Pembrolizumab alone in Patients with Advanced Non-small cell lung cancer (NSCLC) 2PhII Pembrolizumab/MK-7684 or MK-4830 or MK-5890 or MK-0482
Therapeutic area: Cancer
MSD Inactivated VZV Vaccine Vaccines Cancer Adult Patients with Solid Tumor or Hematologic Malignancy 3PhIII Inactivated VZV Vaccine
Therapeutic area: Cancer
MSD MK6482 Biodrugs/ Drugs Cancer MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies. 3PhIII MK6482
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer First line treatment of recurrent/Metastasic Head and Neck Squamous Cell Carcinoma. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab + Chemotherapy + Radiotherapy in Stage III NSCLC 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Pembrolizumab and lenvatinib in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Pneumococcal vaccine polyvalent Vaccines Infections Pedriatric Prevention of pneumococal infection with V114 3PhIII Pneumococcal vaccine polyvalent
Therapeutic area: Infections
MSD Doravirine Biodrugs/ Drugs Infections HIV Infection 3PhIII Doravirine
Therapeutic area: Infections
MSD Pembrolizumab Biodrugs/ Drugs Cancer Metastatic Triple-Negative Breast Cancer (mTNBC). 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Previously Treated Subjects with Squamous Histology Non-Small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle Invasive Bladder Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Pembrolizumab + lenvatinib por previously untreated advanced or metastatic nccRCC 2PhII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD ZERBAXA Biodrugs/ Drugs Infections Pediatric Subjects with Complicated Intra-Abdominal Infection 2PhII ZERBAXA
Therapeutic area: Infections
MSD HIF Triplet (MK6482 + Pembrolizumab + Lenvatinib), CTLA4 Triplet (MK1308A + Lenvatinib), Pembrolizumab/lenvatinib Biodrugs/ Drugs Cancer Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) 3PhIII HIF Triplet (MK6482 + Pembrolizumab + Lenvatinib), CTLA4 Triplet (MK1308A + Lenvatinib), Pembrolizumab/lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Lenalidomide and low dose dexamethasone with Pembrolizumab in Newly diagnosed and treated naive Multiple Myeloma. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer MSI-H or dMMR Stage IV Colorectal Carcinoma treatment naïve 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Adjuvant chemotherapy plus pembrolizumab/placebo for endometrial cancer after surgery with curative intent 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD RSV vaccine Biodrugs/ Drugs Infections VRS prevention in preterm and risk infants 3PhIII RSV vaccine
Therapeutic area: Infections
MSD MK 3475/Pembrolizumab +MK5890/MK4830/Lenvatinib + Etoposide/Platinum Biodrugs/ Drugs Cancer Platform trial: To Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination w/Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants w/Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99) 2PhII MK 3475/Pembrolizumab +MK5890/MK4830/Lenvatinib + Etoposide/Platinum
Therapeutic area: Cancer
MSD MK6482 Biodrugs/ Drugs Cancer MK-6482 Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL) and Pancreatic Neuroendocrine Tumor (pNET) 2PhII MK6482
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Neoadjuvant registration study -Triple negative breast cancer. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Stereotactic Body Radiotherapy (SBRT) with Pembrolizumab or Placebo 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab in Previously Treated Subjects with Selected Solid Tumors 2PhII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Posaconazole Biodrugs/ Drugs Infections Posaconazole for the treatment of invasive aspergillosis in adults and adolescents. 3PhIII Posaconazole
Therapeutic area: Infections
MSD CAVATAK/Pembrolizumab Biodrugs/ Drugs Cancer Study of ITu V937 in Combination with Pembrolizumab selected solid tumors 2PhII CAVATAK/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer First line study of pembrolizumab +/- epacadostat in NSCLC. 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced/Unresectable or Metastatic Bladder Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with metastatic Castration-Resistant Prostate Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Subjects with KRASG12C Mutant Advanced Solid Tumors 1PhI Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD ZERBAXA Biodrugs/ Drugs Respiratory and Pulmonary system Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients 1PhI ZERBAXA
Therapeutic area: Respiratory and Pulmonary system
MSD Golimumab Biodrugs/ Drugs Autoimmune & Inflammation Non-radiographic axial Spondyloarthritis 4Reg. Golimumab
Therapeutic area: Autoimmune & Inflammation
MSD Pembrolizumab Biodrugs/ Drugs Cancer Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in participants with Advanced Endometrial Cancer. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in recurrent or metastatic cutaneous squamous cell carcinoma 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer "Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)" 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for Squamous Non Small cell Lung cancer 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD MK6482 + pembrolizumam / pembrolizumab + placebo Biodrugs/ Drugs Cancer Pembrolizumab + belzutifan vs pembrolizumab + placebo in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy 3PhIII MK6482 + pembrolizumam / pembrolizumab + placebo
Therapeutic area: Cancer
MSD MK6482 + lenvatinib / cabozantinib Biodrugs/ Drugs Cancer MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy. 3PhIII MK6482 + lenvatinib / cabozantinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced or metastatic clear-cell renal cell carcinoma. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Neoadjuvant treatment Platinum Doublet Chemotherapy +/- Pembrolizumab followed by Surgery. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for First Line Therapy of Advanced melanoma 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Posaconazole Biodrugs/ Drugs Infections Prophylaxis of invasive fungal infections in immunocompromised pediatric subjects with neutropenia or expected neutropenia 1PhI Posaconazole
Therapeutic area: Infections
MSD CAVATAK/Pembrolizumab Biodrugs/ Drugs Cancer V937 in Combination with Pembrolizumab Versus Pembrolizumab Alone in Participants with Advanced/Metastatic Melanoma 2PhII CAVATAK/Pembrolizumab
Therapeutic area: Cancer
MSD MK0482 Biodrugs/ Drugs Cancer MK-0482 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid tumors 1PhI MK0482
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab in first line (1L) metastatic non-squamous NSCLC 3PhIII Pembrolizumab
Therapeutic area:
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Advanced Renal Cell Carcinoma (RCC) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab Plus Docetaxel versus Placebo Plus Docetaxel in Patients with Chemotherapy-Naïve metastatic Castration-Resistant Prostate Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib/Belzutifan Biodrugs/ Drugs Cancer Pembrolizumab Plus Lenvatinib in combination with Belzutifan in solid tumors 2PhII Pembrolizumab/Lenvatinib/Belzutifan
Therapeutic area: Cancer
MSD Zilovertamab Vedotin (MK2140) Biodrugs/ Drugs Cancer A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma 2PhII Zilovertamab Vedotin (MK2140)
Therapeutic area: Cancer
MSD Gefapixant Biodrugs/ Drugs Respiratory and Pulmonary system Chronic cough 3PhIII Gefapixant
Therapeutic area: Respiratory and Pulmonary system
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in Combination with Cisplatin and 5-Fluorouracil as First Line treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in children and young adults with newly diagnosed Classical Hodgkin Lymphoma 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Pembrolizumab/Chemotherapy Followed by Pembrolizumab and Maintenance Olaparib for non Squamous Non Small cell Lung cancer 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Molnupiravir Biodrugs/ Drugs Infections
Respiratory and Pulmonary system
Molnupiravir in non-hospitalized patients with COVID-19 3PhIII Molnupiravir
Therapeutic area: Infections / Respiratory and Pulmonary system
MSD MK6482 + lenvatinib + Pembrolizumab Biodrugs/ Drugs Cancer Multiple Solid Tumors 2PhII MK6482 + lenvatinib + Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer PD-L1 Strong Metastatic Non-Small Cell Lung Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Phase II, Pembrolizumab combined with chemotherapy as a First line treatment for NSCLC. 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for Second Line Therapy of Advanced melanoma post anti-PD1b inhibitor 2PhII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Prevymis (Letermovir) Biodrugs/ Drugs Infections Prevention of CMV disease in D+/R- kidney transplant recipients 3PhIII Prevymis (Letermovir)
Therapeutic area: Infections
MSD MK1084 + Pembrolizumab Biodrugs/ Drugs Cancer A Phase 1 Study with MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors 1PhI MK1084 + Pembrolizumab
Therapeutic area: Cancer
MSD Mavezelimab/Pembrolizumab Biodrugs/ Drugs Cancer 4 Select Advanced Solid Tumors 1PhI Mavezelimab/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Study of Pembrolizumab/Epacadostat/ Chemotherapy in Metastatic Non-small Cell Lung Cancer. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab vs chemotherapy in patients with advanced melanoma. 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab or Placebo Plus Enzalutamide/ADT in subjects with Metastatic Hormono-Senmsitive Prostate Cancer (mHSPC) 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/MK1308 or MK1308 + Lenvatinib or MK1308 + MK4830 or MK4280 Biodrugs/ Drugs Cancer Platform trial: Pembrolizumab in combination with Investigational Agents in PD-1/L1-refactory Extensive stage small cell lung Cancer in need of second-line therapy. 2PhII Pembrolizumab/MK1308 or MK1308 + Lenvatinib or MK1308 + MK4830 or MK4280
Therapeutic area: Cancer
MSD ZINPLAVA Biodrugs/ Drugs Infections in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. difficile Infection (Toxin B) 3PhIII ZINPLAVA
Therapeutic area: Infections
MSD Gardasil 9 Vaccines Infections 9vHPV vaccine in adult males 20 to 45 years of age 3PhIII Gardasil 9
Therapeutic area: Infections
MSD MK1308A (quavonlimab+pembro) Biodrugs/ Drugs Cancer Multicenter,Multi Arm,Evaluate Pembrolizumab (MK-3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants w/Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008) 2PhII MK1308A (quavonlimab+pembro)
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have progressed after First Line Standard Therapy. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer 20 Select Advanced Solid Tumors 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab via Subcutaneous Injection of MK-3475A, a Formulation of Pembrolizumab With MK-5180, in Participants with Advanced Solid Tumors. 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Phase III first line chemotherapy plus pembrolizumab + olaparib for BRCA non-mutated advanced EOC (epitelial ovarian cancer) 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Molnupiravir Biodrugs/ Drugs Infections
Respiratory and Pulmonary system
Molnupiravir in adults residing with a person with COVD-19 3PhIII Molnupiravir
Therapeutic area: Infections / Respiratory and Pulmonary system
MSD Nemtabrutinib Biodrugs/ Drugs Cancer A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies. 2PhII Nemtabrutinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer 1st Line mTNBC choice of Taxane +/- Pembro-Triple negative breast cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Phase III Pembro + Chemotherapy in Persistent, Recurrent or Metastatic Cervical Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Pemetrexed + Platinum Chemotherapy + Pembrolizumab with or without Lenvatinib in first line (1L) metastatic non-squamous NSCLC 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Prevymis (Letermovir) Biodrugs/ Drugs Infections Pediatric participants from birth to less than 18 years of age at risk of developing CMV infection and/or disease following allogeneic haematopoietic stem cell transplantation (HSCT) 2PhII Prevymis (Letermovir)
Therapeutic area: Infections
MSD Lenvatinib Biodrugs/ Drugs Cancer Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies 2PhII Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer First Line Study of Pembrolizumab +/- Ipilimumab in NSCLC 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer MSI-H or dMMR Stage IV Colorectal Carcinoma (after progression of First and second line Standard Therapy) 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Subcutaneous Injection Versus Intravenous Infusion in Participants with Advanced Melanoma 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/MK-7684 Biodrugs/ Drugs Cancer Pembrolizumab in combination with anti-TIGIT or Pembrolizumab in combination with anti-TIGIT plus Docetaxel in metastasic non small lung cancer with progressive disease after treatment with a platinum doublet chemotherapy or immunotheraphy 2PhII Pembrolizumab/MK-7684
Therapeutic area: Cancer
MSD Anacetrapib Biodrugs/ Drugs Cardiovascular and circulatory systems Coronary Heart Disease (CHD) or CHD Risk- Equivalent Disease 3PhIII Anacetrapib
Therapeutic area: Cardiovascular and circulatory systems
MSD Gardasil 9 Vaccines Infections VPH in preadolescents and adolescents 3PhIII Gardasil 9
Therapeutic area: Infections
MSD MK-1308A/Lenvatinib Biodrugs/ Drugs Cancer MK-1308A (Coformulated MK-1308/MK-3475), plus Lenvatinib (E7080/MK-7902) in First-line Therapy of Advanced Hepatocellular Carcinoma 2PhII MK-1308A/Lenvatinib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembro Combination Dose Escalation/MTD (IT)-Solid tumour-Rigontec GmbH-INTRATUMOR 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Phase 2 study of pembrolizumab and chemotherapy in patients with newly diagnosed classical Hodgkin Lymphoma 2PhII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Olaparib in combination with Pembrolizumab in Participants with solid tumors Previously Treated 2PhII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab / Olaparib Biodrugs/ Drugs Cancer Pembrolizumab in combination w/concurrent chemoradiation therapy followed by Pembrolizumab w/or w/o Olaparib,compared to concurrent chemoradiation therapy alone in participants w/newly diagnosed treatment-Naïve limited-Stage Small Cell Lung Cancer(LS-SCL 3PhIII Pembrolizumab / Olaparib
Therapeutic area: Cancer
MSD Olaparib Biodrugs/ Drugs Cancer "Olaparib vs Olaparib + Bevacizumab vs 5FU + Bevacizumab in metastasic colorectal cancer". 3PhIII Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab versus standard Treatment in subjects with recurrent or metastatic Head and Neck Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Phase III extension study for participants with advanced tumors in pembrolizumab trials 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Pembrolizumab + lenvatinib versus docetaxel for metastatic NSCLC after platinum doublet chemotherapy and immunotherapy 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD Prevymis (Letermovir) Biodrugs/ Drugs Infections Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients 3PhIII Prevymis (Letermovir)
Therapeutic area: Infections
MSD MK1454/Pembrolizumab Biodrugs/ Drugs Cancer Intratumoral MK-1454 plus Pembrolizumab First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma 2PhII MK1454/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Progressive or recurrent Intermediate or High risk, Non-muscle invasive bladder Cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer 10 Select Advanced Solid Tumors 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer 1L dMMR Endometrial Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer 2PhII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab / Olaparib Biodrugs/ Drugs Cancer Study of Olaparib Plus Pembrolizumab versus Chemotherapy Plus Pembrolizumab after induction of Clinical Benefit With First-line Chemotherapy Plus Pembrolizumab in Participants with locally recurrent inoperable or Metastatic Triple Negative Breast Cancer 2PhII Pembrolizumab / Olaparib
Therapeutic area: Cancer
MSD BET Inhibitor Biodrugs/ Drugs Cancer 4 Select Advanced Solid Tumors 1PhI BET Inhibitor
Therapeutic area: Cancer
MSD Olaparib Biodrugs/ Drugs Cancer "Olaparib Monotherapy in Participants with Previously treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer". 2PhII Olaparib
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer ER+Neoadjuvant -Breast-Oestrogen receptor positive breast cancer 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembrolizumab in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Phase III Pembrolizumab Plus Lenvatinib Versus Chemotherapy for the First-line Treatment of Persistent, Recurrent or Metastatic Endometrial Carcinoma 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD RECARBRIO (mk7655A) Biodrugs/ Drugs Infections Pediatric Participants From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Bacterial Infection 3PhIII RECARBRIO (mk7655A)
Therapeutic area: Infections
MSD MK-3655 Biodrugs/ Drugs Digestive System MK-3655 in Individuals with Pre-Cirrhotic Nonalcoholic Steatohepatitis. 2PhII MK-3655
Therapeutic area: Digestive System
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab plus Epacadostat vs SOC (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in subjects with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab /7684A Biodrugs/ Drugs Cancer Study of MK-7684A plus Chemotherapy versus Pembrolizumab plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer 3PhIII Pembrolizumab /7684A
Therapeutic area: Cancer
MSD Pembrolizumab+ MK7684 (Vibostolimab) Biodrugs/ Drugs Cancer A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies 2PhII Pembrolizumab+ MK7684 (Vibostolimab)
Therapeutic area: Cancer
MSD Pembrolizumab/Olaparib Biodrugs/ Drugs Cancer Pembrolizumab in combination w/concurrent chemoradiation therapy followed by Pembrolizumab w/or w/o Olaparib compared w/concurrent chemoradiation therapy followed by Durvalumab in participants w/unresectable,Locally Advanced,STIII Non-Small Cell Lung Canc 3PhIII Pembrolizumab/Olaparib
Therapeutic area: Cancer
MSD Anti CTLA-4/Pembrolizumab Biodrugs/ Drugs Cancer MK-1308 in Combination with Pembrolizumab vs MK1308 alone in Subjects with Advanced Solid Tumors (Melanoma Expansion Phase) 2PhII Anti CTLA-4/Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in subjects with relapsed or refractory classical Hodgkin Lymphoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Selected Advanced Solid Tumors. 1PhI Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for first Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma 3PhIII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD RIG-I Biodrugs/ Drugs Cancer Advanced/Metastatic or Recurrent Solid Tumors 1PhI RIG-I
Therapeutic area: Cancer
MSD MK4280A (favezelimab+pembro) Biodrugs/ Drugs Cancer A Phase 3 study of MK-4280A [co-formulated favezelimab (MK-4280) plus pembrolizumab (MK-3475)] Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer 3PhIII MK4280A (favezelimab+pembro)
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Adjuvant Therapy with Pembrolizumab Vs. Placebo in Resected Stage II Melanoma. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab Versus Placebo as Adjuvant Therapy in High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab + Lenvatinibb Biodrugs/ Drugs Cancer Previously untreated advanced or metastatic nccRCC 2PhII Pembrolizumab + Lenvatinibb
Therapeutic area: Cancer
MSD Pembrolizumab+MK5890 o MK4830 o Lenvatinib + Etoposido/Platinum Biodrugs/ Drugs Cancer Platform trial: Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or CarboplatinThe first-line treatment of participants with extensive-stage small cell lung cancer 2PhII Pembrolizumab+MK5890 o MK4830 o Lenvatinib + Etoposido/Platinum
Therapeutic area: Cancer
MSD Vericiguat Biodrugs/ Drugs Cardiovascular and circulatory systems HFrEF - heart failure with reduced ejection fraction (in colaboration with Roche) 3PhIII Vericiguat
Therapeutic area: Cardiovascular and circulatory systems
MSD Pembrolizumab Biodrugs/ Drugs Cancer Patients with a histologically confirmed diagnosis of melanoma (MEL) with unresectable or metastatic disease that have not received ipilimumab (IPI) treatment. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Lenvatinib Biodrugs/ Drugs Cancer Lenvatinib plus Pembrolizumab for Second Line Therapy of recurrent/metastatic head and neck squamous cell carcinoma have progressed after platinum therapy and post anti-PD1b inhibitor 2PhII Pembrolizumab/Lenvatinib
Therapeutic area: Cancer
MSD V-937/Pembrolizumab Biodrugs/ Drugs Cancer Clinical Study of Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) in Participants with Advanced/Metastatic Solid Tumors 2PhII V-937/Pembrolizumab
Therapeutic area: Cancer
MSD MK4830 Biodrugs/ Drugs Cancer MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid tumors 1PhI MK4830
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Advanced Gastric or Gastroesophageal Junction Adenocarcinoma First line. 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab Biodrugs/ Drugs Cancer Pembrolizumab in advanced Merkel Cell Carcinoma (MCC) 3PhIII Pembrolizumab
Therapeutic area: Cancer
MSD Pembrolizumab/Enfortumab Biodrugs/ Drugs Cancer Perioperative Pembrolizumab for Cis-Ineligible Muscle Invasive Bladder Cancer 3PhIII Pembrolizumab/Enfortumab
Therapeutic area: Cancer
MSD pembrolizumab+MK6482+lenvatinib / MK1308A + lenvatinib Biodrugs/ Drugs Cancer Pembrolizumab (in Combination with MK-6482 and Lenvatinib, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment for ccRCC 3PhIII pembrolizumab+MK6482+lenvatinib / MK1308A + lenvatinib
Therapeutic area: Cancer
MSD MK1308A , MK4280A, MK6482, MK4830, Pembrolizumab and Lenvatinib Biodrugs/ Drugs Cancer Umbrella trial Immune & Targeted Combin Therapies as 1st line treatm in RCC subj w/MK1308A+Lenva or MK4280A+Lenva or MK 6482+Pembro+Lenva vs Pembro+Lenva or as 2nd line & beyond treatm in RCC subj w/MK1308A or MK4280A or MK4830+Pembro or MK6482+Pembro+Len 2PhII MK1308A , MK4280A, MK6482, MK4830, Pembrolizumab and Lenvatinib
Therapeutic area: Cancer
Novo Nordisk Pharma Concizumab Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A and B 2PhII Concizumab
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Liraglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 in paediatric population 3PhIII Liraglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Nonacog beta pegol Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia B 4Reg. Nonacog beta pegol
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma N8-GP (glycopegylated recombinant FVIII) Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 3PhIII N8-GP (glycopegylated recombinant FVIII)
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Faster-acting insulin aspart (FIAsp) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 and type 2 4Reg. Faster-acting insulin aspart (FIAsp)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma IDegAsp (combination insulin degludec + insulin aspart) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 and type 1 4Reg. IDegAsp (combination insulin degludec + insulin aspart)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Monoclonal antibody anti Il-21 Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 1 2PhII Monoclonal antibody anti Il-21
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma IDegLira (combination insulin degludec + liraglutide) Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 4Reg. IDegLira (combination insulin degludec + liraglutide)
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Oral semaglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 3PhIII Oral semaglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Liraglutide 3mg Biodrugs/ Drugs Metabolic / Endocrinology Obesity 4Reg. Liraglutide 3mg
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Turoctocog alfa Biodrugs/ Drugs Blood and Lymphatic systems Haemophilia A 4Reg. Turoctocog alfa
Therapeutic area: Blood and Lymphatic systems
Novo Nordisk Pharma Semaglutide Biodrugs/ Drugs Metabolic / Endocrinology Diabetes type 2 3PhIII Semaglutide
Therapeutic area: Metabolic / Endocrinology
Novo Nordisk Pharma Somapacitan(Long-acting growth hormone) Biodrugs/ Drugs Metabolic / Endocrinology Growth hormone deficiency 3PhIII Somapacitan(Long-acting growth hormone)
Therapeutic area: Metabolic / Endocrinology
Roche MERICITABINE Biodrugs/ Drugs Infections Chronic viral haepatitis 2PhII MERICITABINE
Therapeutic area: Infections
Roche VENETOCLAX Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII VENETOCLAX
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII AVASTIN
Therapeutic area: Cancer
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasm of kidney except renal pelvis 2PhII APITOLISIB
Therapeutic area: Cancer
Roche SEMBRAGILINE Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII SEMBRAGILINE
Therapeutic area: Central Nervous System
Roche ALEGLITAZAR Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Atherosclerosis 3PhIII ALEGLITAZAR
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Other malignant neoplasms of skin 1PhI DULIGOTUZUMAB
Therapeutic area: Cancer
Roche TAMIFLU Biodrugs/ Drugs Infections Influenza 1PhI TAMIFLU
Therapeutic area: Infections
Roche HPV16 TI Biodrugs/ Drugs Infections Viral agents as cause of diseases classified to other 2PhII HPV16 TI
Therapeutic area: Infections
Roche NEORECORMON Biodrugs/ Drugs Blood and Lymphatic systems Anaemia in neoplastic disease 2PhII NEORECORMON
Therapeutic area: Blood and Lymphatic systems
Roche OCRELIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 3PhIII OCRELIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche TASELISIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI TASELISIB
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of brain 2PhII ONARTUZUMAB
Therapeutic area: Cancer
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI APITOLISIB
Therapeutic area: Cancer
Roche XOLAIR Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Dermatitis (Allergic Contact) 3PhIII XOLAIR
Therapeutic area: Autoimmune & Inflammation / Dermatology
Roche DALCETRAPIB Biodrugs/ Drugs Cardiovascular and circulatory systems Acute myocardial infarction 3PhIII DALCETRAPIB
Therapeutic area: Cardiovascular and circulatory systems
Roche BASIMGLURANT Biodrugs/ Drugs Genetic Diseases and Dysmorphic syndromes Fragile X Syndrome 2PhII BASIMGLURANT
Therapeutic area: Genetic Diseases and Dysmorphic syndromes
Roche VANUCIZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII VANUCIZUMAB
Therapeutic area: Cancer
Roche ALEGLITAZAR Biodrugs/ Drugs Metabolic / Endocrinology Diabetes Mellitus 3PhIII ALEGLITAZAR
Therapeutic area: Metabolic / Endocrinology
Roche EM RA PRED DEV Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 1PhI EM RA PRED DEV
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche TASPOGLUTIDE Biodrugs/ Drugs Metabolic / Endocrinology Diabetes Mellitus 3PhIII TASPOGLUTIDE
Therapeutic area: Metabolic / Endocrinology
Roche IGF1R MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII IGF1R MAB
Therapeutic area: Cancer
Roche PATECLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII PATECLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche OCRELIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Systemic lupus erythematosus 3PhIII OCRELIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche VANUCIZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI VANUCIZUMAB
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII ONARTUZUMAB
Therapeutic area: Cancer
Roche APITOLISIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI APITOLISIB
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Autoimmune & Inflammation Other disorders involving the immune mechanism 3PhIII ACTEMRA
Therapeutic area: Autoimmune & Inflammation
Roche DALCETRAPIB Biodrugs/ Drugs Cardiovascular and circulatory systems
Metabolic / Endocrinology
Atherosclerosis 3PhIII DALCETRAPIB
Therapeutic area: Cardiovascular and circulatory systems / Metabolic / Endocrinology
Roche CMV ANTI Biodrugs/ Drugs Infections Cytomegaloviral disease 2PhII CMV ANTI
Therapeutic area: Infections
Roche ALPHA7 NIC AGO Biodrugs/ Drugs Central Nervous System Alzheimer's disease 2PhII ALPHA7 NIC AGO
Therapeutic area: Central Nervous System
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant melanoma of skin 3PhIII COBIMETINIB
Therapeutic area: Cancer
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 3PhIII ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche VALCYTE Biodrugs/ Drugs Autoimmune & Inflammation Transplanted organ and tissue status (Excl. complications) 3PhIII VALCYTE
Therapeutic area: Autoimmune & Inflammation
Roche IGF1R MAB Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII IGF1R MAB
Therapeutic area: Cancer
Roche POLATUZUMAB VEDOTIN Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Follicular (nodular) non-Hodgkin's lymphoma 2PhII POLATUZUMAB VEDOTIN
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII PDL1 MAB
Therapeutic area: Cancer
Roche VENETOCLAX Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 1PhI VENETOCLAX
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche PARSATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII PARSATUZUMAB
Therapeutic area: Cancer
Roche BRAF KIN INH (2) Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI BRAF KIN INH (2)
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Cardiovascular and circulatory systems Peripheral Vascular Diseases 3PhIII ACTEMRA
Therapeutic area: Cardiovascular and circulatory systems
Roche HCV POL INH PRO Biodrugs/ Drugs Infections Chronic viral haepatitis 3PhIII HCV POL INH PRO
Therapeutic area: Infections
Roche CRENEZUMAB Biodrugs/ Drugs Central Nervous System Alzheimer's disease 3PhIII CRENEZUMAB
Therapeutic area: Central Nervous System
Roche ANTI-INFLUENZA A Biodrugs/ Drugs Infections Influenza 2PhII ANTI-INFLUENZA A
Therapeutic area: Infections
Roche ETROLIZUMAB Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Irritable bowel syndrome 3PhIII ETROLIZUMAB
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 1PhI IMGATUZUMAB
Therapeutic area: Cancer
Roche XELODA Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 3PhIII XELODA
Therapeutic area: Cancer
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII IMGATUZUMAB
Therapeutic area: Cancer
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII TARCEVA
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche CD40 IMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CD40 IMAB
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of kidney except renal pelvis 2PhII PDL1 MAB
Therapeutic area: Cancer
Roche CEA IL2V Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CEA IL2V
Therapeutic area: Cancer
Roche ACTEMRA Biodrugs/ Drugs Metabolic / Endocrinology Thyrotoxicosis (hyperthyroidism) 3PhIII ACTEMRA
Therapeutic area: Metabolic / Endocrinology
Roche ALECTINIB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 3PhIII ALECTINIB
Therapeutic area: Cancer
Roche LAMPALIZUMAB Biodrugs/ Drugs Ophthalmology and optometry Retinal disorders other 4Reg. LAMPALIZUMAB
Therapeutic area: Ophthalmology and optometry
Roche DANOPREVIR Biodrugs/ Drugs Infections Chronic viral haepatitis 2PhII DANOPREVIR
Therapeutic area: Infections
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of cervix uteri 2PhII AVASTIN
Therapeutic area: Cancer
Roche GANTENERUMAB Biodrugs/ Drugs Central Nervous System Alzheimer's disease 3PhIII GANTENERUMAB
Therapeutic area: Central Nervous System
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI IMGATUZUMAB
Therapeutic area: Cancer
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant neoplasms 3PhIII ZELBORAF
Therapeutic area: Cancer
Roche IMGATUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII IMGATUZUMAB
Therapeutic area: Cancer
Roche TARCEVA Biodrugs/ Drugs Cancer Malignant neoplasm of pancreas 2PhII TARCEVA
Therapeutic area: Cancer
Roche ONARTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII ONARTUZUMAB
Therapeutic area: Cancer
Roche CEA CD3 TCB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CEA CD3 TCB
Therapeutic area: Cancer
Roche PICTILISIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII PICTILISIB
Therapeutic area: Cancer
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI COBIMETINIB
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of brain 3PhIII AVASTIN
Therapeutic area: Cancer
Roche BITOPERTIN Biodrugs/ Drugs Central Nervous System Schizophrenia 3PhIII BITOPERTIN
Therapeutic area: Central Nervous System
Roche MABTHERA Biodrugs/ Drugs Cardiovascular and circulatory systems Other necrotizing vasculopathies 3PhIII MABTHERA
Therapeutic area: Cardiovascular and circulatory systems
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of colon/rectum 2PhII DULIGOTUZUMAB
Therapeutic area: Cancer
Roche ERIVEDGE Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII ERIVEDGE
Therapeutic area: Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI IPATASERTIB
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche XELODA Biodrugs/ Drugs Cancer Malignant neoplasm of other and ill-defined sites 2PhII XELODA
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 3PhIII PDL1 MAB
Therapeutic area: Cancer
Roche CIF MEK INH Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI CIF MEK INH
Therapeutic area: Cancer
Roche PICTILISIB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII PICTILISIB
Therapeutic area: Cancer
Roche COBIMETINIB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI COBIMETINIB
Therapeutic area: Cancer
Roche AVASTIN Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 3PhIII AVASTIN
Therapeutic area: Cancer
Roche OCRELIZUMAB Biodrugs/ Drugs Central Nervous System Musculoskeletal Disorders 3PhIII OCRELIZUMAB
Therapeutic area: Central Nervous System
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Follicular (nodular) non-Hodgkin's lymphoma 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Autoimmune & Inflammation
Dermatology
Pemphigus 3PhIII MABTHERA
Therapeutic area: Autoimmune & Inflammation / Dermatology
Roche DULIGOTUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasms 2PhII DULIGOTUZUMAB
Therapeutic area: Cancer
Roche ERIVEDGE Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII ERIVEDGE
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of prostate 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche ZELBORAF Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 2PhII ZELBORAF
Therapeutic area: Cancer
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII PERJETA
Therapeutic area: Cancer
Roche EM MS BIOMARKER Biodrugs/ Drugs Autoimmune & Inflammation
Digestive System
Crohn's disease 1PhI EM MS BIOMARKER
Therapeutic area: Autoimmune & Inflammation / Digestive System
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Diffuse non-Hodgkin's lymphoma, unspecified 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche EM ACTEMAB RA Biodrugs/ Drugs Autoimmune & Inflammation
Musculoskeletal Disorders
Rheumatoid arthritis 2PhII EM ACTEMAB RA
Therapeutic area: Autoimmune & Inflammation / Musculoskeletal Disorders
Roche ERIVEDGE Biodrugs/ Drugs Autoimmune & Inflammation
Cancer
Other disorders involving the immune mechanism 2PhII ERIVEDGE
Therapeutic area: Autoimmune & Inflammation / Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche IPATASERTIB Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 2PhII IPATASERTIB
Therapeutic area: Cancer
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 3PhIII PERJETA
Therapeutic area: Cancer
Roche LIFASTUZUMAB VEDOTIN Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 1PhI LIFASTUZUMAB VEDOTIN
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Lymphoid leukaemia 2PhII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche FORTOVASE Biodrugs/ Drugs Infections HIV disease unspecified 2PhII FORTOVASE
Therapeutic area: Infections
Roche GAZYVA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Malignant neoplasms of lymphoid haematopoietic + 3PhIII GAZYVA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche LUMRETUZUMAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI LUMRETUZUMAB
Therapeutic area: Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of bronchus and lung 2PhII KADCYLA
Therapeutic area: Cancer
Roche PERJETA Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII PERJETA
Therapeutic area: Cancer
Roche OX40 Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI OX40
Therapeutic area: Cancer
Roche MABTHERA Biodrugs/ Drugs Blood and Lymphatic systems
Cancer
Other + unspecif. types of non-Hodgkin's lymphoma 3PhIII MABTHERA
Therapeutic area: Blood and Lymphatic systems / Cancer
Roche GAZYVA Biodrugs/ Drugs Cancer Malignant neoplasm of other and unspecified parts of biliary tract 3PhIII GAZYVA
Therapeutic area: Cancer
Roche HERCEPTIN Biodrugs/ Drugs Cancer Malignant neoplasm of bladder 2PhII HERCEPTIN
Therapeutic area: Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII KADCYLA
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI PDL1 MAB
Therapeutic area: Cancer
Roche PLGF MAB Biodrugs/ Drugs Cancer Malignant neoplasm without specification of site 1PhI PLGF MAB
Therapeutic area: Cancer
Roche LEBRIKIZUMAB Biodrugs/ Drugs Respiratory and Pulmonary system Other diseases of upper respiratory tract 2PhII LEBRIKIZUMAB
Therapeutic area: Respiratory and Pulmonary system
Roche TASELISIB Biodrugs/ Drugs Cancer Malignant neoplasm of breast 3PhIII TASELISIB
Therapeutic area: Cancer
Roche PEGASYS Biodrugs/ Drugs Infections Chronic viral haepatitis 3PhIII PEGASYS
Therapeutic area: Infections
Roche GPC3 MAB Biodrugs/ Drugs Cancer Malignant neoplasm of liver 2PhII GPC3 MAB
Therapeutic area: Cancer
Roche LIFASTUZUMAB VEDOTIN Biodrugs/ Drugs Cancer Malignant neoplasm of ovary 2PhII LIFASTUZUMAB VEDOTIN
Therapeutic area: Cancer
Roche KADCYLA Biodrugs/ Drugs Cancer Malignant neoplasm of stomach 3PhIII KADCYLA
Therapeutic area: Cancer
Roche PDL1 MAB Biodrugs/ Drugs Cancer Malignant neoplasms 1PhI PDL1 MAB
Therapeutic area: Cancer